Schoop, et al.
Nat'l Stage of PCT/S. 0/00120
Page 2 of 2

15 and 16 have been added. No new matter has been added by way of these claim amendments and additions.

More specifically, there are two occurrences of claim 13 in the application. Applicants have deleted the second such claim and rewritten it as new claim 16. Claims 13 and 14 have been amended to convert the Swiss-type use claim to the U.S. method of treatment format and to remove improper multiple claim dependencies. Finally, alternative claim language from claim 14 has been deleted and rewritten as new claim 15. Applicants submit that such amendments do not change the scope of the subject matter claimed in original claims 13 and 14, but merely puts it in an alternative format. All claim amendments made therefore merely address formalities in the claim format and do not change the scope of the claims. Such claim amendments are therefore not related to the patentability of the subject matter claimed.

Conclusion

Applicants respectfully submit that the pending claims, as amended, are in condition for allowance. Please charge any fees due with this amendment to deposit account number 13-3372. If the Examiner believes that a conversation with Applicants' attorney would be helpful in expediting prosecution of this application, the Examiner is invited to call the undersigned attorney at (203) 812-3964.

Respectfully submitted,

Bayer Corporation

400 Morgan Lane

West Haven, CT 06516

(Tel) (203) 812-3964

(Fax) (203) 812-5492

e-mail: jerrie.chiu.b@bayer.com

Jerrie L. Chiu

Attorney for Applicants

Reg. No. 41,670

13. (Amended) Pharmaceutical composition, comprising at least one compound according to Claim 1 and a pharmaceutically acceptable carrier.

-13(a). eanceled-

A2

14. (Amended) A method of treating or preventing angiogenesis and/or cancer, osteolytic diseases, arteriosclerosis, restenosis, rheumatoid arthritis and ophthalmic disorders, comprising administering to a mammal an effective amount of a compound according to Claim 1.



- 15. (New) The method of claim 14, wherein said osteolytic disease is osteoporosis.
- 16. (New) A method of treating or preventing an integrin-mediated disease or condition, comprising administering to a mammal an effective amount of an integrin antagonist according to claim 1.

Amended Claims for Attorney Docket No. Le A 33 364 Version with Markings to Show Changes Made

- 13. (Amended) Pharmaceutical composition, comprising at least one compound according to [one of] Claim[s] 1 [to 9] and a pharmaceutically acceptable carrier.
- 13(a). canceled
- 14. (Amended) A method of treating or preventing [Use of compounds according to one of Claims 1 to 10 for the production of a pharmaceutical composition for the inhibition of] angiogenesis and/or [for the therapy and prophylaxis of] cancer, osteolytic diseases [such as osteoporosis], arteriosclerosis, restenosis, rheumatoid arthritis and ophthalmic disorders, comprising administering to a mammal an effective amount of a compound according to Claim 1.